Request Demo
Last update 14 Jun 2025
Acrixolimab
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms YBL 006, YBL-006 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 651437587H
Source: *****
Sequence Code 651437588L
Source: *****
Related
1
Clinical Trials associated with AcrixolimabNCT04450901
A Phase 1/2a, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors
100 Clinical Results associated with Acrixolimab
Login to view more data
100 Translational Medicine associated with Acrixolimab
Login to view more data
100 Patents (Medical) associated with Acrixolimab
Login to view more data
100 Deals associated with Acrixolimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Jul 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 01 Jul 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Thailand | 01 Jul 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Advanced Malignant Solid Neoplasm TIL | TMB-H | MSI-H | - | azbpswyizc(eicbdabbxb) = dturylckez penqxilhmj (wxxxewlwwn ) View more | Positive | 02 Nov 2023 | ||
NCT04450901 (ASCO2022) Manual  | Phase 1 | 67 | qdzyvekjwi(xnrrobgvcz) = fatigue (19.4%), pruritus (10.4%), and fever (7.5%), and two hypothyroidism (3.0%), one pneumonitis (1.5%), and one cytokine-releasing syndrome (1.5%) were observed. udchhissmu (kfnzmvyliy ) View more | Positive | 02 Jun 2022 | ||
YBL-006 200 mg Q2W | |||||||
Phase 1 | 10 | gcwjyosiyo(mvtjseeqzf) = ffixegmkbd fzbpddvfsu (qdntjdktsy ) | Positive | 16 Sep 2021 | |||
Phase 1 | 8 | ayojppjnaf(qphibgougw) = msvfgizeuv whhragzymp (fswclmfmdg ) | - | 28 May 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free